Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Valion Bio, Inc. - Common stock
(NQ:
VBIO
)
2.140
-0.070 (-3.17%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Valion Bio, Inc. - Common stock
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
Today 7:45 EDT
Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹ Medical countermeasures need to scale...
From
Valion Bio, Inc.
Via
ACCESS Newswire
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
October 05, 2026
Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data and...
From
Valion Bio, Inc.
Via
ACCESS Newswire
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
September 30, 2026
Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimod program Next study will test whether the formulation delivers measurable amounts of Entolimod...
From
Valion Bio, Inc.
Via
ACCESS Newswire
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
September 23, 2026
Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities
From
Valion Bio, Inc.
Via
ACCESS Newswire
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
September 22, 2026
Nasdaq confirms compliance with continued listing standard and closes the matter
From
Valion Bio, Inc.
Via
ACCESS Newswire
Valion Bio Announces Changes to Management and Board of Directors
September 01, 2026
From
Valion Bio, Inc.
Via
ACCESS Newswire
Valion Bio Announces Reverse Stock Split
August 27, 2026
From
Valion Bio, Inc.
Via
ACCESS Newswire
Kartoon Studios (NYSE: TOON) Enters Next Growth Phase; Reports Q2 Revenue of $5.82M, EPS of $0.38 and $40.5M Cash Position – Plus More in Focus
August 14, 2026
Via
AB Newswire
Topics
Intellectual Property
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
August 13, 2026
From
Valion Bio, Inc.
Via
ACCESS Newswire
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury
August 12, 2026
From
Valion Bio, Inc.
Via
ACCESS Newswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
